CNSX:RQB - Ravenquest Biomed Stock Price, News & Analysis

Today's Range N/A
50-Day Range
$0.38
MA: $0.46
$0.54
52-Week Range N/A
Volume74,304 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
RavenQuest BioMed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities. The company operates in two segments, Consulting Business, and Cultivation and Sale of Medical Cannabis. It offers its products under the Lore Cannabis and Bloomera brand names. The company was formerly known as Ravencrest Resources Inc. and changed its name to RavenQuest BioMed Inc. in September 2017. RavenQuest BioMed Inc. was incorporated in 1987 and is based in Vancouver, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-484-1230

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive RQB News and Ratings via Email

Sign-up to receive the latest news and ratings for RQB and its competitors with MarketBeat's FREE daily newsletter.


Ravenquest Biomed (CNSX:RQB) Frequently Asked Questions

What is Ravenquest Biomed's stock symbol?

Ravenquest Biomed trades on the CNSX under the ticker symbol "RQB."

What price target have analysts set for RQB?

1 analysts have issued 1 year target prices for Ravenquest Biomed's shares. Their predictions range from $2.09 to $2.09. On average, they expect Ravenquest Biomed's share price to reach $2.09 in the next twelve months. View Analyst Price Targets for Ravenquest Biomed.

What is the consensus analysts' recommendation for Ravenquest Biomed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ravenquest Biomed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ravenquest Biomed.

Has Ravenquest Biomed been receiving favorable news coverage?

News coverage about RQB stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ravenquest Biomed earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Ravenquest Biomed.

Who are some of Ravenquest Biomed's key competitors?

What other stocks do shareholders of Ravenquest Biomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ravenquest Biomed investors own include Hydropothecary (THCX), Aurora Cannabis (ACB), Canopy Growth (WEED), ICC Labs (ICC), Cannabix Technologies (BLO), Aurora Cannabis (ACB), Sunoco (SUN), MedReleaf (LEAF), Roots (ROOT) and FSD Pharma (HUGE).

Who are Ravenquest Biomed's key executives?

Ravenquest Biomed's management team includes the folowing people:
  • Mr. W. George Robinson, CEO, Pres & Director
  • Ms. Marla K. Ritchie, Corp. Sec. (Age 56)

How do I buy shares of Ravenquest Biomed?

Shares of RQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ravenquest Biomed's official website?

The official website for Ravenquest Biomed is http://www.rqbglobal.com/.

How can I contact Ravenquest Biomed?

The company can be reached via phone at 604-484-1230.


MarketBeat Community Rating for Ravenquest Biomed (CNSX RQB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  47
MarketBeat's community ratings are surveys of what our community members think about Ravenquest Biomed and other stocks. Vote "Outperform" if you believe RQB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RQB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel